Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Standard treatment + Yiyuancong is a combination therapy being investigated for the treatment of sudden sensorineural hearing loss (SSNHL). It consists of standard Western medical treatment (typically involving corticosteroids) combined with Yiyuancong, an independently developed traditional Chinese medicine (TCM) formula. Yiyuancong is prepared as an herbal paste based on the principle of the homology of medicine and food. The therapy is designed to improve audiological outcomes, such as pure-tone audiometry (PTA) thresholds, by leveraging the potential synergistic effects of integrated traditional Chinese and Western medicine. The development of this formula and its clinical evaluation are led by Guangdong Provincial People's Hospital.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on standard treatment + Yiyuancong.